Last Updated 11 December 2014
The HIV therapy market is highly dynamic. Over the past ten years, many effective antiretroviral therapies (ARTs) have been introduced, prompting changes in treatment guidelines and clinical practices. Over the next ten years, the HIV market will increase and then decline as generic erosion of preferred agents constrains market growth driven by uptake of newer therapies. In general, current and emerging brands that simplify treatment regimens through fixed-dose combinations (FDCs) or single-tablet regimens (STRs) will find favorable uptake. Notably, market share for stand-alone integrase inhibitors and integrase inhibitor-based FDCs will expand based on their higher efficacy, better safety, and greater barrier to drug resistance, which are hallmarks of this class of ART.

Questions Answered in This Report:

  • What is the current market landscape for the treatment of HIV? How will emerging therapies compete with well-entrenched brands?

  • How will simplification of treatment regimens (e.g., lower pill burden and less frequent dosing) guide physician prescribing practices for the treatment of HIV patients?

  • What will be the impact of generic erosion and price competition on current market leaders such as Gilead’s Atripla and Truvada?

  • How will changing prevalence, diagnosis, and drug-treated rates for HIV and AIDS affect the overall market growth?

  • What are experts saying about new treatment guidelines recommending treatment of HIV patients irrespective of CD4-positive T-cell levels?

  • What emerging therapies and/or interventions have the potential for a “functional cure” of HIV infections?


Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.

Primary research: Approximately 20 country-specific interviews with HIV thought leaders.

Epidemiology: Total HIV prevalence, diagnosed prevalence, drug-treated population, and newly diagnosed HIV cases.

Emerging therapies: Phase II: 13 drugs; Phase III: 2 drugs; preregistration/registration: 5 drugs.

Author(s): Maria Ascano, Ph.D.
Lade Ayodele, M.B.B.S., M.P.H.